ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma

A randomized phase 2 study

Paolo Strati, Michelle A Fanale, Yasuhiro Oki, Francesco Turturro, Luis E Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee

Research output: Contribution to journalLetter

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)e65-e67
JournalHaematologica
Volume104
Issue number2
DOIs
StatePublished - Jan 31 2019

Fingerprint

Hodgkin Disease
Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma : A randomized phase 2 study. / Strati, Paolo; Fanale, Michelle A; Oki, Yasuhiro; Turturro, Francesco; Fayad, Luis E; Bartlett, Nancy L.; Gladstone, Douglas E.; Kasamon, Yvette L.; Portlock, Carol S.; Wilson, Wyndham H.; Goy, Andre; Younes, Anas; Lee, Hun Ju.

In: Haematologica, Vol. 104, No. 2, 31.01.2019, p. e65-e67.

Research output: Contribution to journalLetter

Strati, P, Fanale, MA, Oki, Y, Turturro, F, Fayad, LE, Bartlett, NL, Gladstone, DE, Kasamon, YL, Portlock, CS, Wilson, WH, Goy, A, Younes, A & Lee, HJ 2019, 'ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study', Haematologica, vol. 104, no. 2, pp. e65-e67. https://doi.org/10.3324/haematol.2018.199844
Strati, Paolo ; Fanale, Michelle A ; Oki, Yasuhiro ; Turturro, Francesco ; Fayad, Luis E ; Bartlett, Nancy L. ; Gladstone, Douglas E. ; Kasamon, Yvette L. ; Portlock, Carol S. ; Wilson, Wyndham H. ; Goy, Andre ; Younes, Anas ; Lee, Hun Ju. / ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma : A randomized phase 2 study. In: Haematologica. 2019 ; Vol. 104, No. 2. pp. e65-e67.
@article{7cd71aaf2d644aa193a132a037550ec2,
title = "ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study",
author = "Paolo Strati and Fanale, {Michelle A} and Yasuhiro Oki and Francesco Turturro and Fayad, {Luis E} and Bartlett, {Nancy L.} and Gladstone, {Douglas E.} and Kasamon, {Yvette L.} and Portlock, {Carol S.} and Wilson, {Wyndham H.} and Andre Goy and Anas Younes and Lee, {Hun Ju}",
year = "2019",
month = "1",
day = "31",
doi = "10.3324/haematol.2018.199844",
language = "English (US)",
volume = "104",
pages = "e65--e67",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "2",

}

TY - JOUR

T1 - ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma

T2 - A randomized phase 2 study

AU - Strati, Paolo

AU - Fanale, Michelle A

AU - Oki, Yasuhiro

AU - Turturro, Francesco

AU - Fayad, Luis E

AU - Bartlett, Nancy L.

AU - Gladstone, Douglas E.

AU - Kasamon, Yvette L.

AU - Portlock, Carol S.

AU - Wilson, Wyndham H.

AU - Goy, Andre

AU - Younes, Anas

AU - Lee, Hun Ju

PY - 2019/1/31

Y1 - 2019/1/31

UR - http://www.scopus.com/inward/record.url?scp=85060939152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060939152&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.199844

DO - 10.3324/haematol.2018.199844

M3 - Letter

VL - 104

SP - e65-e67

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -